Eastern Isotopes distributes Iodine 124, inks agreement with VCU
Eastern Isotopes Inc., a subsidiary of IBA (Ion Beam Applications), made its first delivery of Iodine 124 to MD Anderson Cancer Center, Houston, Texas. The company also has signed a master collaboration agreement with Virginia Commonwealth University (VCU).
Iodine 124 is a PET (positron emission tomography) isotope used for investigational purposes. Due to its relatively long half-life and the ease of attaching it to peptide antibodies for oncology purposes and free fatty acids for cardiology purposes, Iodine 124 is suitable for researchers looking for new radiopharmaceuticals to expand the current PET imaging applications.
According to Eastern Isotopes, the objectives of the collaboration with VCU will be to promote and facilitate the use of nuclear imaging for early, accurate detection of disease and for appropriate management and treatment of disease and to make advanced imaging technology readily available.
The areas of collaboration include: target development for production of PET radionuclitides with high clinical and research potential; discovery and development of new radiopharmaceuticals; development of imaging protocols; and further the education of the user community.
Iodine 124 is a PET (positron emission tomography) isotope used for investigational purposes. Due to its relatively long half-life and the ease of attaching it to peptide antibodies for oncology purposes and free fatty acids for cardiology purposes, Iodine 124 is suitable for researchers looking for new radiopharmaceuticals to expand the current PET imaging applications.
According to Eastern Isotopes, the objectives of the collaboration with VCU will be to promote and facilitate the use of nuclear imaging for early, accurate detection of disease and for appropriate management and treatment of disease and to make advanced imaging technology readily available.
The areas of collaboration include: target development for production of PET radionuclitides with high clinical and research potential; discovery and development of new radiopharmaceuticals; development of imaging protocols; and further the education of the user community.